Ray Riju, Dos Santos Gaël, Buck Philip O, Claeys Carine, Matias Gonçalo, Innis Bruce L, Bekkat-Berkani Rafik
a GSK , Wavre , Belgium.
b Business & Decision Life Sciences , Brussels , Belgium (on behalf of GSK).
Hum Vaccin Immunother. 2017 Jul 3;13(7):1640-1652. doi: 10.1080/21645515.2017.1313375. Epub 2017 May 22.
The contribution of influenza B to the seasonal influenza burden varies from year-to-year. Although 2 antigenically distinct influenza B virus lineages have co-circulated since 2001, trivalent influenza vaccines (TIVs) contain antigens from only one influenza B virus. B-mismatch or co-circulation of both B lineages results in increased morbidity and mortality attributable to the B lineage absent from the vaccine. Quadrivalent vaccines (QIVs) contain both influenza B lineages. We reviewed currently licensed QIVs and their value by focusing on the preventable disease burden. Modeling studies support that QIVs are expected to prevent more influenza cases, hospitalisations and deaths than TIVs, although estimates of the case numbers prevented vary according to local specificities. The value of QIVs is demonstrated by their capacity to broaden the immune response and reduce the likelihood of a B-mismatched season. Some health authorities have preferentially recommended QIVs over TIVs in their influenza prevention programmes.
乙型流感对季节性流感负担的贡献每年都有所不同。自2001年以来，两种抗原性不同的乙型流感病毒谱系同时流行，但三价流感疫苗（TIV）仅包含一种乙型流感病毒的抗原。B型不匹配或两种B谱系同时流行会导致因疫苗中缺乏的B谱系而导致发病率和死亡率增加。四价疫苗（QIV）包含两种乙型流感谱系。我们通过关注可预防的疾病负担，回顾了目前已获许可的QIV及其价值。模型研究支持，与TIV相比，QIV预计可预防更多流感病例、住院和死亡，尽管根据当地具体情况，预防病例数的估计有所不同。QIV的价值体现在其拓宽免疫反应和降低B型不匹配季节可能性的能力上。一些卫生当局在其流感预防计划中优先推荐QIV而非TIV。
